Cilostazol Cardiovascular Effects and Management

Mechanism and Cardiovascular Effects

• Cilostazol is a PDE III inhibitor that increases intracellular cyclic AMP (cAMP), which accounts for both its vasodilatory effects and potential cardiovascular side effects. 1

• The vasodilatory effect is one of the primary mechanisms by which cilostazol improves symptoms in patients with intermittent claudication. 2, 3

Documented Side Effects and Contraindications

• Common cardiovascular side effects of cilostazol include palpitations and dizziness. 2, 3

• Cilostazol is absolutely contraindicated in patients with heart failure of any severity due to the increased risk of ventricular tachycardia. 1

• The FDA has mandated a black-box warning that cilostazol should not be used in patients with heart failure. 2, 3

Clinical Management Considerations

• Approximately 20% of patients discontinue cilostazol within the first 3 months due to side effects, including cardiovascular effects. 4

• For patients requiring long-term cilostazol therapy, evaluate tolerance at 2-4 weeks after initiation. 4

• Assess clinical benefit within 3-6 months of starting therapy. 4

• Consider dose reduction to 50 mg twice daily if the standard dose of 100 mg twice daily causes intolerable hypotension or other cardiovascular side effects. 2, 3

Monitoring Recommendations

• Be vigilant for symptoms of hypotension such as dizziness, lightheadedness, or syncope. 2, 3

• If significant hypotension occurs, consider dose reduction or discontinuation of the medication. 4